Paper30034945
First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
Tang X and 13 others. Am J Cancer Res, 2018. Cited by 410 papers, by iCite.
Cite this record
ConductScience Library. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Papers, record 30034945. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30034945
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016058 | NCI NIH HHS | United States | P30CA016058 | PubMed and NIH | NIH RePORTER |
| R01 AI129582 | NIAID NIH HHS | United States | R01AI129582 | PubMed and NIH | NIH RePORTER |
| R01 CA185301 | NCI NIH HHS | United States | R01CA185301 | PubMed and NIH | NIH RePORTER |
| R01 NS106170 | NINDS NIH HHS | United States | R01NS106170 | PubMed and NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 30323981 | Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. | https://conductscience.org/library/papers/30323981 |
Source PubMed
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25340009 | Are natural killer cells superior CAR drivers? | Oncoimmunology | 2014 | https://conductscience.org/library/papers/25340009 | PubMed |
| 2 | 12149207 | Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. | Blood | 2002 | https://conductscience.org/library/papers/12149207 | PubMed |
| 3 | 24596416 | Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. | Blood | 2014 | https://conductscience.org/library/papers/24596416 | PubMed |
| 4 | 24067492 | CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. | Leukemia | 2014 | https://conductscience.org/library/papers/24067492 | PubMed |
| 5 | 8152260 | Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. | Leukemia | 1994 | https://conductscience.org/library/papers/8152260 | PubMed |
| 6 | 26640245 | ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. | J Natl Cancer Inst | 2016 | https://conductscience.org/library/papers/26640245 | PubMed |
| 7 | 26155832 | CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. | Sci Rep | 2015 | https://conductscience.org/library/papers/26155832 | PubMed |
| 8 | 28496177 | Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. | Leukemia | 2017 | https://conductscience.org/library/papers/28496177 | PubMed |
| 9 | 28725044 | Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. | Leukemia | 2018 | https://conductscience.org/library/papers/28725044 | PubMed |
| 10 | 25113226 | Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. | Leukemia | 2015 | https://conductscience.org/library/papers/25113226 | PubMed |
| 11 | 27008316 | CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. | J Cell Mol Med | 2016 | https://conductscience.org/library/papers/27008316 | PubMed |
| 12 | 27248327 | Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. | Oncotarget | 2016 | https://conductscience.org/library/papers/27248327 | PubMed |
| 13 | 28838796 | NK cell-based immunotherapy for cancer. | Semin Immunol | 2017 | https://conductscience.org/library/papers/28838796 | PubMed |
| 14 | 25373520 | Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. | Mol Ther | 2015 | https://conductscience.org/library/papers/25373520 | PubMed |
| 15 | 27050072 | A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. | Oncotarget | 2016 | https://conductscience.org/library/papers/27050072 | PubMed |
Cited by337
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 410 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42926223 | CAR-NK cell immunotherapy: a comprehensive review of engineering platforms, clinical applications in hematological and solid tumors. | J Cancer Res Clin Oncol | 2026 | https://conductscience.org/library/papers/42926223 | PubMed |
| 42846440 | Therapeutic reprogramming of natural killer cells for solid tumors: expanding frontiers into rare and ultra-rare malignancies. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/42846440 | PubMed |
| 42769371 | Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42769371 | PubMed |
| 42755912 | Progress in reprogramming failed graft-versus-leukemia immunity in acute myeloid leukemia relapse after allogeneic transplantation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42755912 | PubMed |
| 42712866 | iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers. | Front Immunol | 2026 | https://conductscience.org/library/papers/42712866 | PubMed |
| 42665995 | Novel targeted therapy and cellular immunotherapy enabling allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia. | Chin Med J (Engl) | 2026 | https://conductscience.org/library/papers/42665995 | PubMed |
| 42662149 | Immunotherapy in Asia: current insights and prospects in Southeast Asia and Malaysia. | Front Oncol | 2026 | https://conductscience.org/library/papers/42662149 | PubMed |
| 42519392 | Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42519392 | PubMed |
| 42488645 | Enhancing CAR-NK persistence to unlock its full therapeutic potentials. | Front Immunol | 2026 | https://conductscience.org/library/papers/42488645 | PubMed |
| 42349415 | Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42349415 | PubMed |
| 42316255 | Next-generation CAR-NK cell therapy: engineering strategies, translational challenges, and future perspectives in cancer immunotherapy. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42316255 | PubMed |
| 42279415 | Development of Genetically Modified ARH-77 Feeder Cells for Efficient Expansion of Natural Killer Cells with Potent Anti-Tumor Activity. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279415 | PubMed |
| 42243832 | Exploring CAR cell therapies beyond CAR-T for myeloid malignancies. | J Biomed Sci | 2026 | https://conductscience.org/library/papers/42243832 | PubMed |
| 42179676 | Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapy. | Mol Ther Adv | 2026 | https://conductscience.org/library/papers/42179676 | PubMed |
| 42157284 | Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42157284 | PubMed |
| 42082268 | CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42082268 | PubMed |
| 42039438 | CELLISA - a cell-cell binding assay for evaluation of nanovesicle targeting proteins. | bioRxiv | 2026 | https://conductscience.org/library/papers/42039438 | PubMed |
| 42034501 | Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure. | Blood Rev | 2026 | https://conductscience.org/library/papers/42034501 | PubMed |
| 42005464 | A novel cultivation strategy to recover NK cell cytotoxicity. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/42005464 | PubMed |
| 41969284 | Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy. | Cancer Commun (Lond) | 2026 | https://conductscience.org/library/papers/41969284 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD33 | 945 | PubTator's text mining | https://conductscience.org/library/genes/945 | NCBI Gene |
| CXADRP1 | 653108 | PubTator's text mining | https://conductscience.org/library/genes/653108 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30034945
GET https://conductscience.org/api/papers/v1/30034945/cited_by?page=2